WILLIAM S REARDON
CIK 1212646 · last filed 2021-04-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$93.0K
Companies
8
Total Filings
46
Lifetime Open-Market Net
$158.5K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| THW | Director | 1,946 | $13.12 | $25.5K | $25.0K | 2 | 2021-04-08 |
| THQ | Director | 1,196 | $18.55 | $22.2K | $24.9K | 1 | 2021-03-01 |
| Aceragen, Inc. (IDRA) Delisted | Director | 1,940 | $7.22 | $14.0K | $26.4K | 20 | 2018-06-22 |
| MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Director | 47,120 | — | — | $50.0K | 10 | 2015-07-06 |
| HQL | Director | 1,612 | $19.25 | $31.0K | $14.2K | 2 | 2014-07-01 |
| HQH | Director | 661 | $21.50 | $14.2K | $10.2K | 1 | 2012-03-12 |
| OSCIENT PHARMACEUTICALS CORP (OSCI) Delisted | Director | 2,553 | — | — | $0 | 2 | 2008-06-13 |
| Aceragen, Inc. (IDP) Delisted | Director | 4,008 | — | — | $7.8K | 8 | 2007-10-03 |
Recent Filings · Page 2 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-07-03 | MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Grant (A) | +4,878 | $0 | EDGAR |
| 2014-07-03 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | +2,363 | $6.7K | EDGAR |
| 2014-07-01 | HQL | Buy (P) | +200 | $4.0K | EDGAR |
| 2013-11-15 | MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Buy (P) | +13,333 | $50.0K | EDGAR |
| 2013-09-17 | Aceragen, Inc. (IDRA) Delisted | Buy (P) | +13,561 | $24.6K | EDGAR |
| 2013-08-16 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-07-30 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-07-03 | MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Grant (A) | +4,000 | $0 | EDGAR |
| 2012-07-03 | MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Grant (A) | +5,027 | $0 | EDGAR |
| 2012-06-13 | Aceragen, Inc. (IDRA) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.